Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients

BACKGROUND: Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI), has proven efficacy as the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, there is no standard effective second-line treatment option following progression on lenvatinib therapy. Becau...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jixue, Huang, Peixin, Ge, Ningling, Xu, Xin, Wang, Yanhong, Zhang, Lan, Chen, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459189/
https://www.ncbi.nlm.nih.gov/pubmed/36092355
http://dx.doi.org/10.21037/jgo-22-643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459189/
https://www.ncbi.nlm.nih.gov/pubmed/36092355
http://dx.doi.org/10.21037/jgo-22-643

Ejemplares similares